Clinical trial · Interventional
Targeted and Staged Cyber Knife Combined With Interventional Therapy in the Treatment of MHCC
A Prospective Single-arm Study on Targeted and Staged Cyber Knife Combined With Interventional Therapy in the Treatment of Massive Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hepatocellular carcinoma is a highly malignant tumor that is progressing rapidly. Hepatic arterial embolization chemotherapy (TACE) is a common method for the treatment of unresectable of hepatocellular carcinoma.But for patients with \> 10cm hepatocellular carcinoma, the intervention effect was not satisfied.The cyberknife is a kind of stereotactic radiotherapy which can track the movement of tumor and monitor the position deviation of tumor in real time.This stuy is aimed to observe the efficiency and safety of the combination of TACE and cyberknife in the treatment of massive hepatocellular carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TACE plus Cyber knife | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- combination
- description
- TACE plus cyber knife
- interventionNames
- Radiation: TACE plus Cyber knife
Primary outcomes (2)
- measure
- response rate(RR)
- timeFrame
- 18 months
- description
- CR(complete response)+PR(partial response)
- measure
- overall survival(OS)
- timeFrame
- 26mounth
- description
- Overall survival was defined as the time from enrollment to death from any cause.
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed hepatocellular carcinoma * No lymph node metastasis or distant metastasis * Tumor diameter at least 10 cm * Hepatic lesions are not suitable for surgical resection or the patient refuse to surgical treatment * Eastern Clinical Oncology Group (ECOG)score is 0， 1or2 * No history of abdominal radiotherapy * Inoperable and untransplantable,Child-pugh score A or B * Normal liver volume exceeds 700 cm3 Exclusion Criteria: * Previous history of abdominal radiotherapy; * The maximum diameter of tumor is less than 10cm; * The liver Child is graded C; * Contraindication for radiotherapy; * Active gastrointestinal bleeding occurred within 2 weeks before enrollment * Pregnancy * Undergoing chemotherapy throughout the past six months * Diffuse hepatocellular carcinoma * Main portal vein tumor embolization * Undergoing other simultaneous treatment
References
Publications (0)
Data not yet available